Loading clinical trials...
Loading clinical trials...
Safety and Efficacy of Combivent Respimat in Chronic Obstructive Pulmonary Disease (COPD)
Conditions
Interventions
Atrovent Respimat (20 mcg)
COMBIVENT MDI (36/206 mcg)
+2 more
Locations
180
United States
1012.56.01006 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
1012.56.01051 Boehringer Ingelheim Investigational Site
Jasper, Alabama, United States
1012.56.01071 Boehringer Ingelheim Investigational Site
Mobile, Alabama, United States
1012.56.01039 Boehringer Ingelheim Investigational Site
Phoenix, Arizona, United States
1012.56.01012 Boehringer Ingelheim Investigational Site
Lakewood, California, United States
1012.56.01029 Boehringer Ingelheim Investigational Site
Los Angeles, California, United States
Start Date
November 1, 2006
Primary Completion Date
April 1, 2008
Last Updated
June 13, 2014
NCT06712563
NCT06831994
NCT02755974
NCT05087641
NCT05050591
NCT05913765
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions